This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Discovery Labs Announces Newly-Released SURFAXIN® (lucinactant) Publications

Stocks in this article: DSCO

WARRINGTON, Pa., March 29, 2013 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced the release of two peer-reviewed publications related to SURFAXIN ® (lucinactant) Intratracheal Suspension. SURFAXIN, currently the only FDA approved synthetic alternative to animal-derived surfactants in the U.S., was highlighted in the December issue of the Journal of Pediatric Pharmacology and Therapeutics (JPPT), in an article titled " A Pharmacoeconomic Analysis of In-Hospital Costs Resulting from Reintubation in Preterm Infants Treated with Lucinactant, Beractant, or Poractant Alfa", as well as this month's issue of Expert Reviews in Clinical Pharmacology in an article titled " Lucinactant for the Prevention of Respiratory Distress Syndrome in Premature Infants".

"We believe the growing body of peer-reviewed scientific literature for SURFAXIN will better inform physicians and other decision makers considering formulary adoption of SURFAXIN," said Dr. Russell G. Clayton, Senior Vice President, Research & Development, of Discovery Labs. 

The publications are as follows:

A Pharmacoeconomic Analysis of In-Hospital Costs Resulting from Reintubation in Preterm Infants Treated with Lucinactant, Beractant, or Poractant Alfa JPPT July- September 2012, Vol. 17, No. 3, pp. 220-227

A pharmacoeconomic analysis previously presented at the 2012 Pediatric Academic Society Annual Conference and now published in the most recent issue of JPPT shows the lower rate of reintubation previously observed in infants treated with SURFAXIN, when compared with infants treated with the market leading surfactants, Curosurf ® and Survanta ®, resulted in a potential hospital cost savings associated with a reduction in need for mechanical ventilation. 

Lucinactant for the Prevention of Respiratory Distress Syndrome in Premature Infants - Expert Rev. Clin. Pharmacol. March 2013, Vol. 6, No. 2, Pages 115-121

In an independent review, Expert Reviews authors provide a comprehensive assessment of lucinactant based on a compilation of available peer-reviewed publications that have discussed the safety, efficacy, and potential pharmacoeconomic impact of lucinactant in the prevention of respiratory distress syndrome (RDS). As the first synthetic, peptide-containing surfactant approved by the FDA, the authors indicate that SURFAXIN can be reproducibly manufactured and may reduce certain cultural or religious objections sometimes presented by parents with the use of animal-derived medications in their infants who are at risk for RDS. Furthermore, the authors discuss the future of surfactant replacement therapy, including potential aerosolization of lucinactant, which could allow for a less invasive approach to treating RDS.

IMPORTANT SAFETY INFORMATION SURFAXIN (lucinactant) Intratracheal Suspension is intended for intratracheal use only. The administration of exogenous surfactants, including SURFAXIN, can rapidly affect oxygenation and lung compliance. SURFAXIN should be administered only by clinicians trained and experienced with intubation, ventilator management, and general care of premature infants in a highly supervised clinical setting. Infants receiving SURFAXIN should receive frequent clinical assessments so that oxygen and ventilatory support can be modified to respond to changes in respiratory status.

Most common adverse reactions associated with the use of SURFAXIN are endotracheal tube reflux, pallor, endotracheal tube obstruction, and need for dose interruption. During SURFAXIN administration, if bradycardia, oxygen desaturation, endotracheal tube reflux, or airway obstruction occurs, administration should be interrupted and the infant's clinical condition assessed and stabilized. SURFAXIN is not indicated for use in acute respiratory distress syndrome (ARDS).

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,949.55 +144.75 0.81%
S&P 500 2,077.32 +6.67 0.32%
NASDAQ 4,779.3790 +13.9990 0.29%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs